Cosmos Holdings Inc. Share Price OTC Markets
Stocks
COSM
US2214131078
Pharmaceuticals
OTC Markets Traded|
Delayed
OTC Markets
16:14:35 05/10/2021 BST
|
5-day change | 1st Jan Change | ||
| 4.510 USD | -5.65% |
|
-2.45% | - |
| 09-11 | Cosmos Health Unit Enters 5-Year Contract Manufacturing Deal With Viofar Over Cardiovascular Medicine | MT |
| 09-03 | Cosmos Health Inc. Reaffirms Earnings Guidance for the Year 2026, 2027 and 2029 | CI |
| Market Cap | 38.25M 33.65M 31.72M 28.94M 54.12M 3.67B 54.54M 381M 147M 1.87B 144M 140M 6.08B | P/E 2026 * |
-1.81x | P/E 2027 * | 5.43x |
|---|---|---|---|---|---|
| Enterprise Value | 38.25M 33.65M 31.72M 28.94M 54.12M 3.67B 54.54M 381M 147M 1.87B 144M 140M 6.08B | EV / Sales 2026 * |
0.47x | EV / Sales 2027 * | 0.35x |
| Free-Float |
76.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -5.65% |
| Manager | Title | Age | Since |
|---|---|---|---|
Grigorios Siokas
CEO | Chief Executive Officer | 60 | 25/02/2016 |
Georgios Terzis
DFI | Director of Finance/CFO | 43 | 10/11/2020 |
| Chief Operating Officer | 56 | 31/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 12/01/2014 | |
Grigorios Siokas
CHM | Chairman | 60 | 25/02/2016 |
John Hoidas
BRD | Director/Board Member | 59 | 17/11/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.65% | -2.45% | - | - | 38.25M | ||
| -1.27% | -1.16% | +14.30% | +98.19% | 101B | ||
| +0.61% | -1.64% | +44.02% | +150.25% | 51.55B | ||
| -0.39% | +0.78% | -14.33% | +267.14% | 20.81B | ||
| -0.25% | -0.87% | -11.20% | -10.55% | 7.93B | ||
| -1.66% | -0.34% | -38.67% | -34.93% | 6.8B | ||
| +2.98% | +5.92% | -0.75% | +15.95% | 6.52B | ||
| -0.20% | -0.93% | -19.00% | -33.12% | 5.93B | ||
| +0.46% | +1.29% | -2.25% | +20.48% | 4.95B | ||
| +1.25% | +8.76% | +20.44% | +22.78% | 4.02B | ||
| Average | -0.51% | +0.72% | -0.83% | +55.13% | 23.32B | |
| Weighted average by Cap. | -0.68% | -0.32% | +14.40% | +109.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 80.8M 71.07M 67M 61.13M 114M 7.76B 115M 804M 312M 3.95B 303M 297M 12.85B | 111M 97.46M 91.87M 83.82M 157M 10.64B 158M 1.1B 427M 5.41B 416M 407M 17.61B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COSM Stock
- COSM Stock
Select your edition
All financial news and data tailored to specific country editions
















